-
ESTIMATING MEANINGFUL CHANGE THRESHOLDS (MCTS) FOR EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) SCALES IN A PHASE 3 TRIAL FOR PATIENTS WITH LOCALLY RECURRENT INOPERABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
Mar 18, 2026, 21:38 PM -
EVALUATING AI MODELS FOR DRUG PRICING ANALYTICS: A COMPARATIVE STUDY FOR MOST-FAVORED-NATION POLICY MODELING
Mar 18, 2026, 21:38 PM -
MATCHING-ADJUSTED INDIRECT COMPARISON OF LUVOMETINIB VERSUS SELUMETINIB IN THE TREATMENT FOR PEDIATRIC PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 IN CHINA
Mar 18, 2026, 21:38 PM -
DEVELOPING A PATIENT-REPORTED OUTCOME (PRO) MEASURE FOR JAPANESE PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER (NMCRPC)
Mar 18, 2026, 21:38 PM -
CONTRASTIVE TRAJECTORY DISTILLATION: A NOVEL METHOD FOR OPTIMIZING LARGE LANGUAGE MODEL EMBEDDINGS IN MATERNAL HEALTH PREDICTION
Mar 18, 2026, 21:38 PM -
COMPARATIVE EFFECTIVENESS AND HARMS OF SUSTAINED STATIN THERAPY AMONG YOUNG ADULTS
Mar 18, 2026, 21:38 PM -
FACTORS ASSOCIATED WITH OVERDOSE RISK AMONG PERINATAL WOMEN WITH OPIOID USE DISORDER
Mar 18, 2026, 21:38 PM -
GENERATIVE ARTIFICIAL INTELLIGENCE FOR AUTOMATED HEALTH ECONOMIC MODEL DEVELOPMENT: A PROOF-OF-CONCEPT FRAMEWORK
Mar 18, 2026, 21:38 PM -
BUDGET IMPACT ANALYSIS OF KIRSTY AND MERILOG IN THE TREATMENT OF DIABETES MELLITUS FROM A U.S. PAYER PERSPECTIVE
Mar 18, 2026, 21:38 PM -
WHEN NOT TO USE ARTIFICIAL INTELLIGENCE IN HEALTH ECONOMICS AND OUTCOMES RESEARCH
Mar 18, 2026, 21:38 PM -
IMPACT OF METHOD CHOSEN FOR DEFINING OBSERVABLE TIME IN LINKED OPEN DATA SOURCES
Mar 18, 2026, 21:38 PM -
REAL-WORLD BUDGET IMPACT ANALYSIS OF BIOSIMILAR ADOPTION IN A MEDIUM-SIZED BRAZILIAN HEALTH MAINTENANCE ORGANIZATION (HMO)
Mar 18, 2026, 21:38 PM -
REAL WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND COSTS AMONG PATIENTS WITH ASTHMA RECEIVING BIOLOGIC THERAPY: A TARGETED LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
THE NEED TO CONSIDER THE IMPACT OF DRIVERS OF RELATIVE TREATMENT EFFECTS BEYOND TREATMENT CHOICE IN COST-EFFECTIVENESS ANALYSES (CEA)
Mar 18, 2026, 21:38 PM -
EXPERT CONSENSUS ON TREATMENT GUIDANCE FOR FDA-APPROVED AND SECOND-GENERATION EXON-SKIPPING THERAPIES IN DUCHENE MUSCULAR DYSTROPHY (DMD): A RAND/UCLA MODIFIED DELPHI PANEL
Mar 18, 2026, 21:38 PM -
INCIDENCE OF IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED PNEUMONITIS AMONG NON-SMALL CELL LUNG CANCER PATIENTS WITH AND WITHOUT PRE-EXISTING COPD
Mar 18, 2026, 21:38 PM -
THE IMPACT OF CARING FOR THEIR CHILDREN WITH RETT SYNDROME: A MULTI-METHOD STUDY
Mar 18, 2026, 21:38 PM -
CLINICAL AND HUMANISTIC BURDEN OF ADULT PATIENTS WITH NEUROFIBROMATOSIS TYPE 1 WITH PLEXIFORM NEUROFIBROMA IN THE REAL-WORLD SETTING ACROSS FOUR EUROPEAN COUNTRIES: RESULTS FROM A REAL-WORLD SURVEY
Mar 18, 2026, 21:38 PM -
A NOVEL APPROACH FOR GENERATING ROBUST POPULATION ESTIMATES FOR USE IN HTA AND REGULATORY SUBMISSIONS: DEMONSTRATION IN CLL IN GERMANY
Mar 18, 2026, 21:38 PM -
A MULTI-MODEL LARGE LANGUAGE FRAMEWORK FOR AUTOMATING SYSTEMATIC LITERATURE REVIEWS
Mar 18, 2026, 21:38 PM
